Literature DB >> 20700786

[Pharmacological neuroenhancement and brain doping : Chances and risks].

A G Franke1, K Lieb.   

Abstract

Pharmacological neuroenhancement refers to the use of psychoactive substances by healthy subjects with the purpose of cognitive enhancement, e.g., vigilance, concentration, memory, or mood. "Brain doping", however, refers to the illicit use of a subcategory of these substances such as prescription drugs. This subcategory includes psychostimulants (e.g., amphetamines, methylphenidate), modafinil, antidementia drugs (acetylcholine-esterase inhibitors, memantine), and antidepressants (selective serotonin reuptake inhibitors) which are being prescribed for the treatment of ADHD (attention deficit/hyperactivity disorder), Alzheimer's disease, and depression. Only psychostimulants and modafinil show significant effects on concentration, attentiveness, and vigilance in healthy subjects. However, a general use by healthy persons can not be justified because of relevant side effects and safety risks. Caffeine for pharmacological neuroenhancement can be seen as an equally effective alternative. "Brain doping" raises numerous ethical and social concerns that require a continued discussion. Demands of liberalization should be critically questioned.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20700786     DOI: 10.1007/s00103-010-1105-0

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  17 in total

Review 1.  Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines.

Authors:  A Antal; I Alekseichuk; M Bikson; J Brockmöller; A R Brunoni; R Chen; L G Cohen; G Dowthwaite; J Ellrich; A Flöel; F Fregni; M S George; R Hamilton; J Haueisen; C S Herrmann; F C Hummel; J P Lefaucheur; D Liebetanz; C K Loo; C D McCaig; C Miniussi; P C Miranda; V Moliadze; M A Nitsche; R Nowak; F Padberg; A Pascual-Leone; W Poppendieck; A Priori; S Rossi; P M Rossini; J Rothwell; M A Rueger; G Ruffini; K Schellhorn; H R Siebner; Y Ugawa; A Wexler; U Ziemann; M Hallett; W Paulus
Journal:  Clin Neurophysiol       Date:  2017-06-19       Impact factor: 3.708

2.  Acute effects of lisdexamfetamine and D-amphetamine on social cognition and cognitive performance in a placebo-controlled study in healthy subjects.

Authors:  Patrick C Dolder; Petra Strajhar; Patrick Vizeli; Alex Odermatt; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2018-02-09       Impact factor: 4.530

Review 3.  [Doping for the brain].

Authors:  Bernhard Iglseder
Journal:  Z Gerontol Geriatr       Date:  2017-12-05       Impact factor: 1.281

4.  The use of Ginkgo biloba in healthy elderly.

Authors:  Andreas G Franke; Isabel Heinrich; Klaus Lieb; Andreas Fellgiebel
Journal:  Age (Dordr)       Date:  2013-06-05

5.  What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement.

Authors:  Andreas G Franke; Klaus Lieb; Elisabeth Hildt
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

6.  Evaluating the drivers of and obstacles to the willingness to use cognitive enhancement drugs: the influence of drug characteristics, social environment, and personal characteristics.

Authors:  Sebastian Sattler; Guido Mehlkop; Peter Graeff; Carsten Sauer
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-02-01

7.  Attitudes towards prescribing cognitive enhancers among primary care physicians in Germany.

Authors:  Andreas G Franke; Carolin Papenburg; Elena Schotten; Peter B Reiner; Klaus Lieb
Journal:  BMC Fam Pract       Date:  2014-01-08       Impact factor: 2.497

8.  Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons.

Authors:  Andreas G Franke; Christiana Bagusat; Pavel Dietz; Isabell Hoffmann; Perikles Simon; Rolf Ulrich; Klaus Lieb
Journal:  BMC Med       Date:  2013-04-09       Impact factor: 8.775

9.  Associations between physical and cognitive doping--a cross-sectional study in 2.997 triathletes.

Authors:  Pavel Dietz; Rolf Ulrich; Robert Dalaker; Heiko Striegel; Andreas G Franke; Klaus Lieb; Perikles Simon
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

10.  To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students.

Authors:  Larissa J Maier; Matthias E Liechti; Fiona Herzig; Michael P Schaub
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.